Renalytix (LSE: RENX) (NASDAQ: RNLX) is the founder and global leader in the new field of bioprognosis™ for kidney health. We’ve engineered a proprietary solution that successfully enables early-stage, progression risk assessment when it counts the most. Renalytix. Right here, until kidney disease isn’t.™